background
coronaviru
pandem
current
global
public
health
emerg
present
pharmacolog
treatment
known
treat
condit
need
review
avail
treatment
object
studi
describ
role
chloroquin
hydroxychloroquin
variou
viral
condit
limit
inform
use
systemat
review
aim
summar
avail
evid
regard
role
chloroquin
treat
coronaviru
infect
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
use
review
preprint
yet
peerreview
articl
systemat
review
articl
mention
role
chloroquin
hydroxychloroquin
limit
infect
viru
caus
conclus
theoret
experiment
preclin
clinic
evid
effect
chloroquin
patient
affect
adequ
evid
drug
safeti
longtim
clinic
use
chloroquin
hydroxychloroquin
indic
data
ongo
futur
trial
add
insight
role
chloroquin
hydroxychloroquin
infect
outbreak
sever
acut
respiratori
syndrom
coronaviru
report
wuhan
china
decemb
spread
rest
china
mani
countri
across
globe
global
number
peopl
diagnos
infect
increas
exponenti
declar
pandem
present
pharmacolog
agent
approv
regulatori
agenc
treatment
infect
review
drug
found
effect
need
hour
chloroquin
cq
use
extens
antimalari
agent
immunomodulatori
effect
deriv
cq
hydroxychloroquin
sulfat
hcq
synthes
first
ad
hydroxyl
group
cq
much
less
toxic
cq
anim
studi
cq
use
sar
coronaviru
infect
due
antivir
properti
recent
cq
also
found
activ
vitro
reason
cq
hcq
could
potenti
drug
treat
infect
date
clinic
evid
support
use
cq
hcq
treat
infect
though
mani
clinic
trial
drug
alreadi
underway
studi
aim
systemat
review
avail
literatur
use
cq
hcq
treat
infect
systemat
review
publish
literatur
done
find
role
cq
covid
infect
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
use
review
public
select
studi
includ
abstract
origin
articl
preproof
accept
articl
preprint
case
report
case
seri
letter
editor
expert
opinion
publish
sinc
incept
till
march
investig
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
discuss
role
cq
covid
infect
articl
exclud
studi
duplic
paper
poster
paper
without
mention
role
cq
infect
pubm
googl
scholar
use
search
articl
report
topic
role
cq
covid
infect
search
conduct
use
follow
keyword
chloroquin
hydroxychloroquin
public
time
rang
march
abstract
purpos
articl
found
literatur
search
review
articl
describ
role
cq
hcq
infect
select
fulltext
review
titl
well
abstract
item
search
result
screen
fulltext
select
articl
download
relev
inform
use
cq
hcq
select
articl
extract
data
select
articl
studi
independ
two
investig
kmk
ak
consensu
achiev
mutual
discuss
relev
data
extract
select
articl
two
author
kmk
ak
data
point
tabul
read
full
text
select
articl
number
select
articl
small
find
present
form
tabl
narr
summari
initi
search
role
chloroquin
yield
entri
publish
till
rd
march
use
exclus
criteria
eighteen
item
select
list
includ
five
publish
articl
three
letterscorrespond
one
commentari
four
preproof
accept
articl
one
abstract
yet
publish
articl
four
w
preprint
yet
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
peerreview
articl
one
public
chines
select
review
english
abstract
translat
english
languag
use
googl
translat
servic
chloroquin
cq
wellknown
clinic
use
sinc
hydroxychloroquin
sulfat
hcq
synthes
addit
hydroxyl
group
cq
cq
use
extens
treat
malaria
also
treatment
autoimmun
disord
rheumatoid
arthriti
system
lupu
erythematosu
etc
immunomodulatori
role
cell
entri
ebov
marv
inhibit
due
increas
endosom
ph
cq
due
abil
prevent
acidif
intracellular
organel
data
kinet
chloroquin
uptak
indic
drug
attain
nearmaximum
intracellular
concentr
hr
drug
level
produc
decrement
cellular
biosynthesi
protein
rna
dna
herp
simplex
replic
found
sensit
drug
level
progeni
viru
product
depress
hr
cq
also
affect
viral
replic
inhibit
viral
gene
express
cq
abil
chang
pattern
glycosyl
envelop
vitro
vivo
test
cq
also
inhibit
replic
hiv
viru
cell
cq
hcq
weakli
alkalin
base
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
sever
acut
respiratori
syndrom
coronaviru
highli
pathogen
coronavirus
result
region
global
outbreak
current
clinic
specif
pharmacolog
agent
seven
coronavirus
concentr
rang
ic
inhibit
sarscov
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
cq
found
effect
inhibit
infect
spread
sar
cov
cell
cultur
cq
inhibit
viru
replic
reduc
termin
glycosyl
angiotensinconvert
enzym
receptor
vero
cell
surfac
interf
bind
sarscov
receptor
cq
signific
inhibitori
antivir
effect
suscept
cell
treat
either
infect
suggest
possibl
prophylact
therapeut
use
cq
interfer
attempt
acidifi
lysosom
probabl
inhibit
cathepsin
need
low
ph
optim
cleavag
spike
protein
requir
format
autophagosom
wuhan
cov
sprotein
share
almost
ident
structur
rbd
domain
sarscov
sprotein
although
rel
weaker
sarscov
wuhan
cov
sprotein
strong
bind
affin
human
receptor
henc
wuhan
cov
pose
signific
risk
human
transmiss
due
bind
pathway
like
sarscov
cq
found
function
entri
well
postentri
stage
infect
vero
cell
immunemodul
activ
cq
may
also
synergist
enhanc
antivir
effect
vivo
oral
intak
cq
get
wide
distribut
whole
bodi
includ
lung
valu
chloroquin
vero
cell
achiev
clinic
shown
plasma
rheumatoid
arthriti
patient
receiv
mg
daili
dose
low
cost
good
safeti
profil
make
cq
potenti
clinic
applic
drug
infect
endem
malaria
presenc
seem
protect
certain
popul
infect
especi
least
develop
countri
mechan
action
antimalari
drug
antivir
properti
suggest
potenti
role
chemoprophylaxi
epidem
studi
cq
found
potenti
inhibitor
viral
plpro
effect
chloroquin
postentri
stage
could
manifest
via
inhibit
crucial
viral
protein
plpro
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
suggest
regimen
dutch
cdc
adult
includ
initi
dose
mg
chloroquin
base
follow
mg
h
first
day
follow
mg
twice
daili
day
second
fifth
document
also
emphas
need
stop
treatment
day
reduc
risk
side
effect
cq
long
halflif
hour
also
need
differenti
treatment
base
chloroquin
phosphat
chloroquin
base
sinc
mg
chloroquin
phosphat
equival
mg
chloroquin
base
anoth
set
guidelin
italian
societi
infecti
tropic
diseas
lombardi
section
suggest
use
cq
mg
twice
daili
hcq
mg
daili
ten
day
treatment
durat
vari
day
base
clinic
sever
suggest
target
group
patient
rang
patient
mild
respiratori
symptom
comorbid
patient
sever
respiratori
failur
cq
recommend
year
infect
adult
dose
twice
daili
seven
day
bw
kg
patient
cq
dose
decreas
daili
day
third
seventh
treatment
cycl
tabl
dose
recommend
cq
infect
children
far
henc
extrem
caution
follow
prescrib
children
acut
poison
cq
usual
fatal
dose
mgkg
cq
concentr
moll
fatal
predictor
nigerian
children
acut
uncompl
malaria
chloroquin
absorpt
appear
reliabl
peak
chloroquin
concentr
achiev
within
hour
concentr
declin
slowli
elimin
halflif
day
cq
detect
urin
month
singl
dose
accord
new
coronaviru
pneumonia
diagnosi
treatment
program
trial
version
issu
nation
health
health
commiss
china
recommend
dosag
chloroquin
phosphat
tablet
mg
bid
daili
ten
day
case
sever
gastrointestin
symptom
dose
cq
reduc
mg
daili
even
discontinu
cours
cq
treatment
throat
swab
becom
neg
stay
neg
three
day
drug
withdraw
consid
howev
minimum
cours
cq
treatment
need
least
five
day
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
far
result
patient
treat
cq
shown
chloroquin
phosphat
superior
control
treatment
inhibit
worsen
pneumonia
improv
lung
imag
find
promot
virusneg
convers
shorten
cours
diseas
sever
advers
reaction
cq
seen
patient
drug
recommend
inclus
next
version
guidelin
prevent
diagnosi
treatment
pneumonia
caus
issu
nation
health
commiss
peopl
republ
china
would
first
success
use
cq
human
treat
acut
viral
diseas
howev
inform
care
consid
draw
definit
conclus
support
clinic
data
releas
yet
februari
seven
clinic
trial
registri
found
chines
clinic
trial
registri
use
hcq
treatment
report
safe
dosag
hcq
mgkg
per
day
could
reach
serum
level
human
anim
cq
hcq
share
similar
tissu
distribut
concentr
liver
spleen
kidney
lung
reach
level
time
higher
plasma
therefor
high
concentr
tissu
like
achiev
safe
dosag
hcq
inhibit
infect
possibl
howev
await
confirm
clinic
trial
patient
infect
cq
interact
lopinavirritonavir
caus
qt
interv
prolong
henc
hcq
consid
instead
cq
latter
avail
treatment
hcq
found
potent
cq
inhibit
vitro
hcq
sulfat
mg
twice
daili
one
day
follow
mg
twice
daili
four
day
recommend
treat
infect
base
cq
antivir
mechan
laboratori
activ
well
cq
pharmacokinet
base
use
malaria
autoimmun
diseas
safe
potenti
efficaci
dose
regimen
recommend
protect
protocol
preexposur
prophylaxi
cq
daili
postexposur
prophylaxi
cq
three
day
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
recent
trial
use
hcq
singl
drug
hcq
combin
azithromycin
proport
patient
neg
pcr
result
nasopharyng
sampl
signific
differ
two
group
day
six
posttreat
patient
treat
hcq
azithromycin
combin
virolog
cure
compar
patient
treat
hcq
control
group
contraind
rel
contraind
includ
use
cq
peopl
year
year
pregnant
women
person
allerg
patient
hematolog
disord
defici
patient
chronic
liver
kidney
diseas
patient
arrhythmia
chronic
heart
diseas
patient
histori
retin
diseas
hear
loss
patient
known
mental
ill
skin
diseas
like
rash
dermat
psoriasi
cq
known
drug
interact
variou
drug
expert
medic
opinion
regard
interact
medicin
alreadi
taken
patient
must
mild
side
effect
cq
treat
malaria
includ
headach
dizzi
loss
appetit
etc
primari
advers
reaction
cq
higher
dose
ocular
toxic
could
affect
vision
discomfort
eye
visual
abnorm
occur
cq
discontinu
immedi
side
effect
cq
includ
cardiac
arrhythmia
druginduc
psychosi
leukopenia
etc
combin
cq
heparin
could
increas
risk
bleed
patient
take
digitali
cq
could
caus
cardiac
block
decad
european
visit
malariaendem
area
receiv
chloroquin
prophylaxi
would
continu
two
month
return
use
cq
treatment
malaria
also
use
long
hcq
use
much
higher
dose
mgday
treat
autoimmun
diseas
quit
difficult
find
product
betterestablish
safeti
profil
cq
low
cost
cq
deriv
shown
earli
promis
treat
infect
explor
potenti
drug
prevent
therapeut
role
turn
tide
rapidli
evolv
pandem
disorderli
clinic
trial
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
use
tradit
chines
medicin
western
medicin
ongo
may
abl
give
highqual
clinic
evid
order
death
health
emerg
creat
nation
administr
scientif
research
improv
manag
coordin
improv
studi
qualiti
base
clinic
trial
guidelin
also
recommend
research
role
cq
prevent
also
urg
articl
cq
regimen
investig
parallel
mass
deploy
drug
without
unnecessari
regulatori
delay
attempt
contain
global
pandem
benefit
cq
far
outweigh
risk
cost
result
vitro
studi
recent
clinic
trial
use
cq
hcq
infect
quit
promis
intern
strategi
allow
use
promis
drug
like
cq
hcq
made
consid
low
cost
easi
avail
minim
advers
effect
cq
hcq
prescrib
patient
medic
supervis
trial
drug
throw
light
use
infect
systemat
review
limit
includ
small
sampl
size
public
limit
data
regard
role
cq
hcq
human
infect
howev
current
emerg
circumst
believ
studi
benefici
scientif
commun
gener
public
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
